ICRN/ENS-CCA Translational Science Seminar Series

The Seminar Series is a tool to disseminate emerging basic, translational, and clinical information to interested researchers around the globe with hope of fostering new ideas and deeper collaborations among our membership.

We encourage all ICRN/ENS-CCA Members to participate as a speaker in the ICRN/ENS-CCA Translational Science Seminar Series. If you’d like to present, please contact us.

Upcoming Presentations

December 5, 2024: PSC-related Cholangiocarcinoma – Part 1, Screening Prevention and Early Diagnosis

Past Presentations

ICRN/ENS-CCA Translational Science Seminar Series

September 2024: Breaking New Ground – Advances in Oncolytic Virus Therapy for Cholangiocarcinoma

January 2024: KRAS as a therapeutic target in cholangiocarcinoma

July 2022: Morphomolecular characterization of early and progressed cholangiocarcinoma

June 2022: Opportunities for Innovative Radiopharmaceutical Diagnostics and Therapeutics Discovery for Cholangiocarcinoma

May 2022: Deciphering the role of ZEB1 in the tumor-stroma crosstalk in cholangiocarcinoma

April 2022: Supermassive Intrahepatic CCA: Clinicogenomic Analysis & Role of Ablative Radiotherapy

March 2022: Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

February 2022: Targeting Immunosuppressive Myeloid Cells in Cholangiocarcinoma

December 2021: Challenges of Designing Immune Trials in the Second Line with a Review of Data

October 2021: PSC & cholangiocarcinoma – where the research stands on the interconnection

September 2021: Genomic and Epigenomic Landscape of Cholangiocarcinoma – Cancer Discovery Paper Discussion

August 2021: Genomic and Epigenomic Landscape of Cholangiocarcinoma – Cancer Discovery Paper Discussion

July 2021: Role of Cytotoxic Chemo in Cholangiocarcinoma

June 2021: Next Steps with FGFRi

May 2021: The Cholangiocarcinoma Participant Engagement and Cancer Genome Sequencing U2C Cancer Moonshot Program at Washington University in St. Louis Collapse

April 2021: What is IDH1 mutated cholangiocarcinoma and what else can we do for it?

March 2021: Innovative surgical approaches to cholangiocarcinoma – transplant and beyond

February 2021: MEKi – Where do we go next in cholangiocarcinoma?

January 2021: Ciliotherapy: The Primary Cilium as a Therapeutic Target in Carcinogenesis

December 2020: ARID1A and CCA

November 2020: Introduction to cBioPortal for Cancer Genomics

October 2020: Ablative Radiation for Intrahepatic Cholangiocarcinoma: Current Status and Future Directions

September 2020: Drug Repurposing in Cholangiocarcinoma – Identifying Leads from the Literature

August 2020: Immune Landscape of Cholangiocarcinoma